DBV DBV Technologies SA

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

Montrouge, France, October 31, 2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, at 5:00 p.m. ET to report third quarter 2022 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 94309191#.

  • United States: 866 374 5140                                                
  • Canada: 866 455 3403
  • United Kingdom: 808 238 9813                                                
  • France: 805 102 712

A live webcast of the call will be available on the Investors & Media section of the Company’s website: . A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact

Anne Pollak

DBV Technologies



Media Contact

Angela Marcucci

DBV Technologies

Viaskin and EPIT are trademarks of DBV Technologies.

 

Attachment



EN
31/10/2022

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Positive Topline Results from Phase 3 VITES...

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria a...

6h / 47m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce des résultats préliminaires positifs dans l’é...

DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide VITESSE a atteint son critère d’évaluation principal : la limite inférieure de l’intervalle de confiance à 95 % (IC) à savoir la différence entre les taux de réponse des groupes actif et pl...

6h / 47m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights11/30/2025 200,777,718  Total gross of voting rights: 200,777,718  Total net* of voting rights: 200,667,869  * Net total = total number of voting rights at...

December 2, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions c...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date  Nombre totald’actionscomposant le capital socialNombre totalde droits de vote30/11/2025  200.777.718  Total brut des droits de vote : 200.777.718  Total net* des droits de vote : 200.667.869  *Total net = nombre t...

December 2, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Pha...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the l...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch